Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity are Linked to Clinical Responses to 5-Azacytidine

The DNA methyltransferase inhibitors (DNMTi) 5-azacytidine (AZA) and 5-aza-2-deoxycytidine have been approved for the treatment of different types of hematological malignancies. However, only about 50% of patients respond to treatment. Therefore, a more comprehensive understanding of the molecular c...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Res
Main Authors: Ohtani, Hitoshi, Ørskov, Andreas D., Helbo, Alexandra S., Gillberg, Linn, Liu, Minmin, Zhou, Wanding, Ungerstedt, Johanna, Hellström-Lindberg, Eva, Sun, Weili, Liang, Gangning, Jones, Peter A., Grønbæk, Kirsten
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7507765/
https://ncbi.nlm.nih.gov/pubmed/32245794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-1696
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items